Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Solving "-tinib-itis"
Description
In this presentation, Dr. Mara Beverage discusses the management of skin-related side effects induced by cancer treatments, colloquially termed "-tinib-itis," focusing on the challenges faced by dermatologists when dealing with these complex cases. Dr. Beverage outlines critical questions dermatologists should consider: the type of cancer, timing of diagnosis, current treatment regimen, and drug details. She emphasizes understanding drug classes and their implications for skin reactions, particularly the morphology and distribution of rashes. Through two detailed case studies, she illustrates different dermatological presentations linked to tyrosine kinase inhibitors used in oncology, particularly noting interface dermatitis as a common pattern. The presentation advises on effective management strategies, including supportive care and the potential use of medications like prednisone, hydroxychloroquine, and dupilumab for symptom relief, while highlighting the importance of nuanced treatment approaches given the life-threatening nature of cancer. Dr. Beverage encourages dermatologists to not shy away from oncology-related rashes and to leverage resources like case reports to inform their practice.
View moreConclusions
- The presentation highlights the complexities of diagnosing and treating dermatological side effects related to oncology treatments, particularly those involving tyrosine kinase inhibitors.
- Understanding the morphology, distribution, and treatment regimen of cancer patients is crucial in diagnosing skin rashes associated with their treatments.
- Axitinib, a multi-targeted tyrosine kinase inhibitor, is associated with unique skin reactions including interface dermatitis and hand-foot skin reactions.
- Common dermatological manifestations in oncology patients can exhibit varied morphologies and timelines, requiring dermatologists to consider both oncology-specific and classic drug eruption patterns.
- Interface dermatitis is a prevalent presentation among patients receiving targeted therapy, indicating that dermatologists should be familiar with this condition in the context of cancer treatment.
- Improved communication and collaboration between oncologists and dermatologists can enhance patient care by adequately addressing skin-related treatment side effects.
- Dupilumab shows potential as a therapeutic option for managing lichenoid drug eruptions associated with immunotherapy and other cancer treatments.
- Huang, L., Jiang, S., & Shi, Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 13, 143 (2020). https://doi.org/10.1186/s13045-020-00977-0
- Kim EJ, DeSimone MS, Shi CR. Subacute cutaneous lupus erythematosus following osimertinib therapy for non-small cell lung cancer: A case report. JAAD Case Rep. 2024 Aug 31;53:30-33. doi: 10.1016/j.jdcr.2024.08.015. PMID: 39430640; PMCID: PMC11488431.